Mabpharm Ltd. held its Annual General Meeting on June 18, 2025. The proposals on the agenda included granting a general mandate to the directors to issue, allot, and deal with additional shares of the company, which was approved. Another proposal to extend this general mandate by the aggregate number of shares repurchased by the company was also approved. All proposed resolutions were passed as ordinary resolutions at the meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.